5-Amino-1MQ

Assumed mechanism: 5-amino-1MQ inhibits nicotinamide N-methyltransferase (NNMT), which normally methylates nicotinamide using SAM as the methyl donor (producing 1-methylnicotinamide). NNMT is markedly upregulated in obese white adipose tissue. By inhibiting it, the compound is thought to spare nicotinamide for NAD+ salvage (raising NAD+) and conserve SAM, increasing adipocyte energy expenditure and fat oxidation (via downstream SIRT1/PGC-1a signaling) while suppressing lipogenesis. This is well supported in mice and cells but unproven in humans.

The 'No registered human trial' line is a registry-status statement, so it shows a Status tag rather than a letter.

• People use it for fat loss and metabolic health, stacking it with GLP-1 drugs, GH secretagogues, and peptides. The NNMT target is real and mechanistically compelling.
• The evidence is almost entirely in mice. One key study (Neelakantan 2018) showed significant fat loss in diet-induced obese mice at 20 mg/kg/day. No controlled human trial has been published or registered anywhere.
• The catch is the cancer biology. NNMT is upregulated in a long list of tumors, and inhibiting it chronically in a human system, with no human safety data, is a genuine open question nobody can answer yet.

Adverse events

Reported real-world adverse effects are mild and anecdotal: transient nausea, mild GI/stomach discomfort, occasional headache or jitteriness, mostly early and self-limiting. There is no human safety dataset, no adverse-event registry, and no long-term human data of any kind, so the true frequency and severity of side effects are unknown.

Contraindications

No human contraindications are formally established because there are no trials. Reasonable caution: pregnancy/breastfeeding, active or prior malignancy (given NNMT's cancer associations), significant liver disease, and concurrent methyl-donor or NAD-pathway drugs. Not a substitute for evaluated obesity therapies. Gray-market product purity, identity, and dose accuracy are unverified.

Theoretical concerns

NNMT is upregulated in multiple cancers and participates in liver and CNS one-carbon/SAM metabolism. Chronic systemic NNMT inhibition could theoretically disturb methylation balance (SAM/SAH ratio), nicotinamide/NAD+ handling, and pathways implicated in tumor biology; none of this has been studied in humans. These are mechanism-based concerns, not documented harms.

What nobody knows yet

Essentially everything human: oral bioavailability and PK in people, effective and safe dose, therapeutic window, drug interactions, long-term oncologic and metabolic safety, and whether the striking mouse fat-loss effect translates to humans at all. Tolerance is anecdotally reported after ~4-6 weeks but unverified.

What else could explain the result

Almost always run alongside other interventions that independently drive fat loss: caloric restriction, GLP-1/GIP agonists (tirzepatide/semaglutide), other peptides (e.g., tesamorelin, MOTS-c, AOD-9604), stimulants, training programs, and NAD+ boosters (NMN/NR). Any body-composition change is extremely hard to attribute to 5-amino-1MQ specifically.

Is the vial what it says?

Foundational target biology verified against primary literature: Kraus et al., Nature 2014 (PMID 24717514) and Neelakantan et al., Biochemical Pharmacology 2018 (mouse + cell). NNMT/obesity review PMC8337113 explicitly states clinical trials targeting NNMT have not been reported. ClinicalTrials.gov shows no registered trial of 5-amino-1MQ. Vendor/clinic claims of imminent or 'registered' human trials could not be corroborated and are treated as marketing. Reconstitution/storage and dosing figures are vendor/community sources, flagged as anecdotal.

Half-life and storage

Half-life: No human pharmacokinetic data exist. Rodent/vendor-cited plasma half-life is roughly 4-7 hours (commonly stated ~3.8-6.9 h). Treat as preclinical/unverified for humans.

Once mixed: Sold lyophilized; vendor handling guidance is to store powder frozen (around -20 C), bring to room temperature before opening, reconstitute gently with bacteriostatic water down the vial wall (swirl, do not shake to avoid foaming), then refrigerate the solution at 2-8 C protected from light and use within about 2-4 weeks; do not refreeze. As a small molecule it is generally less fragile than true peptides, but product quality from gray-market sources is unverified.

What people report

Volume of reports: mixed. Reports exist but contradict each other.

Low-to-moderate. There is steady marketing chatter and clinic/vendor content, but genuine independent user-experience volume (forums, long-term self-reports) is thin compared with mainstream peptides like BPC-157 or GLP-1 drugs.

Moderately consistent on the mild, early effects (a slight uptick in energy/focus and modest early scale movement); much less consistent on meaningful fat loss, with many reports describing subtle or hard-to-distinguish results and anecdotal tolerance after a few weeks.

Low. The bulk of positive content originates from vendors, medspas, and affiliate sites with a financial interest; independent, disinterested reports are sparse, and almost all users co-administer other fat-loss interventions, undermining attribution.

• Many users report a mild, stimulant-like lift in energy, focus, and motivation in the first couple of weeks, which is also the effect most prone to placebo. (Anecdote, not proof.)
• Fat-loss reports are generally modest and slow, and most users describe results as subtle or hard to separate from their concurrent diet, training, or GLP-1/peptide use. (Anecdote.)
• A recurring theme is apparent tolerance: perceived effects fade over time. (Anecdote, no mechanism confirmed in humans.)
• Tolerability is usually described as good, with mild early nausea or stomach upset that tends to settle. (Anecdote; no human safety dataset.)

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: No controlled human trial has been completed or published. There is no human Phase 1 dose-finding study, no human pharmacokinetic publication, and no registered ClinicalTrials.gov trial of 5-amino-1MQ itself as of October 2026. Documented human exposure is limited to off-label use via gray-market research-chemical vendors and some wellness/medspa clinics, beginning roughly 2021-2023; none of it is controlled or peer-reviewed.

1. 2014Kraus et al. (Nature) show NNMT knockdown protects mice from diet-induced obesity, validating NNMT as a metabolic target.
2. 2018Neelakantan et al. (Biochemical Pharmacology) report membrane-permeable methylquinolinium NNMT inhibitors (5-amino-1MQ lead) that reverse diet-induced obesity in mice.
3. 2021Review literature (e.g., PMC8337113) frames NNMT inhibition for obesity/T2D while noting no clinical trials have been reported.
4. 2021-20235-Amino-1MQ appears in the gray market as a research chemical and at some wellness/medspa clinics, marketed for fat loss and energy; all human use is off-label and uncontrolled.
5. 2026Still no published human trial or human PK data. In January 2026 FDA told a 503B outsourcing facility that drugs compounded with 5-Amino-1MQ are not eligible for 503B exemptions because it is not on the bulks list. No FDA-approved use.

• Kraus 2014, Nature - NNMT knockdown protects against diet-induced obesity (PMID 24717514)(Founding target-validation study; mice + cells, antisense knockdown. Not 5-amino-1MQ itself, not human.)
• PubMed - methylquinolinium NNMT inhibitors reverse obesity in mice (Neelakantan 2018, Biochemical Pharmacology)(Primary preclinical paper for the 5-amino-1MQ inhibitor class; diet-induced obese mice + adipocytes. Animal/in-vitro only.)
• PubMed - Roles of NNMT in Obesity and Type 2 Diabetes review (PMC8337113)(Review describing 5-amino-1MQ as reversing diet-induced obesity in mice and explicitly noting no NNMT-targeted clinical trials have been reported.)
• ClinicalTrials.gov search - 5-amino-1MQ (0 results, checked 2026-10-12)(No registered human trial of 5-amino-1MQ as of October 2026; confirms the absent-human-data finding.)
• FDA warning letter to a 503B outsourcing facility, January 20, 2026(States 5-amino-1-methylquinolinium iodide is not on the 503B bulks list, so compounding with it does not qualify for the 503B exemptions.)
• PubMed search - NNMT NAD+ SAM adipocyte mechanism(Mechanistic background for the assumed NAD+/SAM-sparing mode of action; cell-level evidence.)
• Neelakantan H et al. Biochem Pharmacol 2018;147:141-152. PMID 29155147(dose table)